Commitment to Research and Development

Our research and development goals are simple: to produce innovative and diverse high quality products, which will fit with customer needs.
To achieve this, the Schering-Plough Corporation invests in excess of
$1 billion in R&D. This puts the Corporation among the top five
investors in the field of pharmaceuticals and animal health research
and development. We rank in the top three worldwide for our speed in bringing new products to the market.

Leaders in many areas, SPAH produces a broad range of products:
anti-infectives, anti-inflammatories, parasiticides, prostaglandins and biologicals – for all the major animal health groups. Worldwide the company is making significant investments in advanced biologicals which offer an alternative to existing products. These vaccines will offer new user-friendly options.

The Corporation has dedicated R&D facilities in ten locations worldwide, including Europe, Australia, South America and at seven sites spread across the US.